SEC ownership of Camp4 Therapeutics Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001736730.
- CIK
- 0001736730
- Symbol
- CAMP on Nasdaq
- Location
- Cambridge, MA
- Parsed ownership evidence
- 13D/G, 13F, and 3/4/5
- Lead holder
- 5AM Ventures VI, L.P.
- 13D/G signal
- 5AM Ventures VI, L.P.
- Latest evidence date
- 31 Mar 2026
Ownership snapshot
Top shareholders of Camp4 Therapeutics Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
5AM Ventures VI, L.P.
13D/G signal
5AM Ventures VI, L.P.
Evidence rows
50
Latest as of
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 12%
13D/G row: 5AM Ventures VI, L.P.
Showing first 8 of 50 holder rows.
Open remaining rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| 5AM Ventures VI, L.P. |
13D/G
Andrew J. Schwab
|
12%
|
$8,392,800
5,869,091 shares
|
$0 | 09 Sep 2025 |
| JANUS HENDERSON GROUP PLC |
13D/G
13F
Company
|
12%
|
$37,908,892
6,307,636 shares
|
$0 | 31 Dec 2025 |
| Coastlands Capital LP |
13D/G
|
10%
|
$21,452,710
4,886,722 shares
|
$0 | 10 Sep 2025 |
| FMR LLC |
13D/G
13F
Company
|
9.5%
|
$28,968,451
4,918,243 shares
|
+$10,440,496 | 31 Dec 2025 |
| Polaris Management Co. VII, L.L.C. |
13D/G
3/4/5
Amir Nashat · 10%+ Owner
|
8.4%
|
$5,623,119
3,932,251 shares
|
$0 | 09 Sep 2025 |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
7.4%
|
$23,373,365
3,856,991 shares
|
+$1,788,900 | 31 Dec 2025 |
| BALYASNY ASSET MANAGEMENT L.P. |
13D/G
13F
Company
|
5.1%
|
$11,819,642
2,632,437 shares
|
$0 | 31 Mar 2026 |
| Enavate Sciences GP, LLC |
13D/G
3/4/5
13F
10%+ Owner · Company
|
4.8%
|
$10,955,517
2,495,562 shares
|
-$2,773,593 | 09 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$8,554,994.
Buys
$8,554,994
Insiders: 7
Sells
$0
Insiders: 0
Net
+$8,554,994
Shares: +5,588,885
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 5,588,885
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 5,588,885 | 0 | $8,554,994 | $0 | +$8,554,994 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Current reporting-owner rows connected to Camp4 Therapeutics Corp. Open the relationship link for the CIK-to-CIK filing trail.
Rows
23
Lead holder
Andrew J. Schwab
Net 12M change
+$8,554,993
Latest report
01 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Andrew J. Schwab | Director, 10%+ Owner | $8,686,917 | Mixed | 11 Sep 2025 | ||
| 5AM Partners VI, LLC | 10%+ Owner | $8,686,917 | +$4,499,999 | +107% | Mixed | 11 Sep 2025 |
| Josh Mandel-Brehm | Chief Executive Officer, Director | $459,388 | +$9,999 | +2.2% | Filing P/S | 01 Apr 2026 |
| Polaris Management Co. VII, L.L.C. | 10%+ Owner | $302,421 | +$1,999,999 | +661% | Filing P/S | 11 Sep 2025 |
| Amir Nashat | Director, 10%+ Owner | $302,421 | +$1,999,999 | +661% | Filing P/S | 11 Sep 2025 |
| Richard A. Young | Director | $280,516 | +$24,999 | +9.8% | Filing P/S | 11 Sep 2025 |
| Kelly Gold | Chief Financial Officer | $111,997 | +$9,999 | +9.8% | Filing P/S | 01 Apr 2026 |
| Yuri Maricich | Chief Medical Officer | $9,999 | +$9,999 | +100% | Filing P/S | 01 Apr 2026 |
| Polaris Partners GP X, L.L.C. | 10%+ Owner | Mixed | 15 Oct 2024 | |||
| Northpond Ventures II GP, LLC | 10%+ Owner | Mixed | 15 Oct 2024 | |||
| Enavate Sciences GP, LLC | 10%+ Owner | Mixed | 15 Oct 2024 | |||
| Murray Stewart | Director | Mixed | 17 Mar 2025 | |||
| Douglas E. Williams | Director | Mixed | 17 Mar 2025 | |||
| Daniel Tardiff | Chief Scientific Officer | Mixed | 01 Apr 2026 | |||
| Steven H. Holtzman | Director | Mixed | 25 Jun 2025 | |||
| Michael F. MacLean | Director | Mixed | 01 Apr 2026 | |||
| James P. Boylan | Director | Mixed | 25 Jun 2025 | |||
| Ravi I. Thadhani | Director | Mixed | 25 Jun 2025 | |||
| Paula Ragan | Director | Mixed | 25 Jun 2025 | |||
| Michael J. Higgins | Director | Mixed | 25 Jun 2025 | |||
| Ingo Chakravarty | Director | Mixed | 10 Oct 2024 | |||
| David Bumcrot | Chief Scientific Officer | Mixed | 01 Apr 2025 | |||
| AH Equity Partners Bio I, L.L.C. | 10%+ Owner | Mixed | 15 Oct 2024 |
Recent Insider Transactions by Companies or Individuals for Camp4 Therapeutics Corp
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Daniel Tardiff | CAMP | Stock Option (Right to Buy) | Award | 170,000 | 170,000 | 01 Apr 2026 | Direct | |||
| Yuri Maricich | CAMP | Stock Option (Right to Buy) | Award | 215,000 | 215,000 | 01 Apr 2026 | Direct | |||
| Kelly Gold | CAMP | Stock Option (Right to Buy) | Award | 215,000 | 215,000 | 01 Apr 2026 | Direct | |||
| Josh Mandel-Brehm | CAMP | Stock Option (Right to Buy) | Award | 580,000 | 580,000 | 01 Apr 2026 | Direct | |||
| Michael F. MacLean | CAMP | Stock Option (Right to Buy) | Award | 56,000 | 56,000 | 01 Apr 2026 | Direct | |||
| Daniel Tardiff | CAMP | Stock Option (Right to Buy) | Award | 145,500 | 145,500 | 11 Dec 2025 | Direct | |||
| Yuri Maricich | CAMP | Stock Option (Right to Buy) | Award | 190,000 | 190,000 | 11 Dec 2025 | Direct | |||
| Kelly Gold | CAMP | Stock Option (Right to Buy) | Award | 190,000 | 190,000 | 11 Dec 2025 | Direct | |||
| Josh Mandel-Brehm | CAMP | Stock Option (Right to Buy) | Award | 425,000 | 425,000 | 11 Dec 2025 | Direct | |||
| Andrew J. Schwab | CAMP | Common Stock | Award | 2,941,176 | 2,941,176 | 11 Sep 2025 | By 5AM Ventures VII, L.P. | |||
| 5AM Partners VI, LLC | CAMP | Common Stock | Purchase | $4,499,999 | $1.53 | 2,941,176 | 2,941,176 | 11 Sep 2025 | By 5AM Ventures VII, L.P. | |
| Polaris Management Co. VII, L.L.C. | CAMP | Common Stock | Purchase | 86.1% | $1,999,999 | $1.53 | 1,307,189 | 2,825,500 | 11 Sep 2025 | See footnote |
| Amir Nashat | CAMP | Common Stock | Purchase | 86.1% | $1,999,999 | $1.53 | 1,307,189 | 2,825,500 | 11 Sep 2025 | See Footnote |
| Yuri Maricich | CAMP | Common Stock | Purchase | $9,999 | $1.65 | 6,060 | 6,060 | 11 Sep 2025 | Direct | |
| Kelly Gold | CAMP | Common Stock | Purchase | 9.8% | $9,999 | $1.65 | 6,060 | 67,877 | 11 Sep 2025 | Direct |
| Josh Mandel-Brehm | CAMP | Common Stock | Purchase | 2.23% | $9,999 | $1.65 | 6,060 | 278,417 | 11 Sep 2025 | Direct |
| Richard A. Young | CAMP | Common Stock | Purchase | 9.78% | $24,999 | $1.65 | 15,151 | 170,010 | 11 Sep 2025 | Direct |
| James P. Boylan | CAMP | Stock Option (Right to Buy) | Award | 9,000 | 9,000 | 25 Jun 2025 | Direct | |||
| Richard A. Young | CAMP | Stock Option (Right to Buy) | Award | 9,000 | 9,000 | 25 Jun 2025 | Direct | |||
| Michael J. Higgins | CAMP | Stock Option (Right to Buy) | Award | 9,000 | 9,000 | 25 Jun 2025 | Direct | |||
| Andrew J. Schwab | CAMP | Stock Option (Right to Buy) | Award | 9,000 | 9,000 | 25 Jun 2025 | Direct | |||
| Steven H. Holtzman | CAMP | Stock Option (Right to Buy) | Award | 9,000 | 9,000 | 25 Jun 2025 | Direct | |||
| Amir Nashat | CAMP | Stock Option (Right to Buy) | Award | 9,000 | 9,000 | 25 Jun 2025 | Direct | |||
| Ravi I. Thadhani | CAMP | Stock Option (Right to Buy) | Award | 9,000 | 9,000 | 25 Jun 2025 | Direct | |||
| Paula Ragan | CAMP | Stock Option (Right to Buy) | Award | 9,000 | 9,000 | 25 Jun 2025 | Direct |
An asterisk next to the price means the reported price is likely invalid.